['diabetes mellitus']
['exenatide', 'exenatide matching placebo']

        Inclusion criteria:

          -  Has a diagnosis of Type 2 Diabetes Mellitus (T2DM)

          -  Has HbA1c of 7.5% to 12.0%, inclusive, at Visit 1 (Screening).

          -  Has fasting plasma glucose (FPG) concentration <280 mg/dL (15.6 mmol/L) at Visit 1
             (Screening)

          -  Treated with basal insulin glargine at a dose of ≥20 units/day once daily for at least
             6 weeks prior to Screening, in combination with diet and exercise alone or in
             combination with:

               1. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1

               2. a stable dose of metformin (≥1500 mg/day) for at least 8 weeks prior to Visit 1
                  (Screening) and a stable dose of sulfonylurea for at least 8 weeks prior to the
                  Screening visit

        Exclusion criteria:

          -  Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)

          -  History of, or currently have, acute or chronic pancreatitis, or have triglyceride
             concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1

          -  Positive serological test for hepatitis B or hepatitis C
      